Otsuka / Astex clinical trial pipeline

9 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 5 with minor changes only.

1. Notable

   JNT-517 · Phenylketonuria (PKU)

   Primary endpoint(s) modified

   Also in this update: Interventions modified

   Otsuka Pharmaceutical Development & Commercialization, Inc.·Phase 3· NCT06971731· Registry history of NCT06971731 on ClinicalTrials.gov (opens the registry)

   Oct 21, 2026

2. Notable

   Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in…Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

   Primary and study completion dates pushed to Dec 2, 2026

   Otsuka Pharmaceutical Development & Commercialization, Inc.·Phase 1· NCT07455084· Registry history of NCT07455084 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Notable

   SEP-363856 · Generalized Anxiety Disorder

   Recruitment opened

   Otsuka Pharmaceutical Development & Commercialization, Inc.·Phase 3· NCT07786454· Registry history of NCT07786454 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

4. Notable

   Healthy Adult Participants and · Autoimmune Disease to Test How…Healthy Adult Participants and · Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

   Recruitment opened

   Otsuka Pharmaceutical Development & Commercialization, Inc.·Phase 1· NCT07649265· Registry history of NCT07649265 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.